Antibody drug conjugatetro Trodelvy significantly improves PFS: Phase III study reaches end in patients with triple-negative breast cancer

Immunomedics announced that its antibody drug, the conjugate Trotecan-hziy, was used in patients with three negativebreast cancer(TNBC), who had previously received at least two anti-metastasis therapies, and that the Phase III ASCENT study reached the primary end point of progression-free survival (PFS)Photo Source:Trodelvy is made up of the highly expressed TROP-2 monoantidotophobic drug (Iliticon) SN-38, an antibody drug conjugate that was approved by theFDAearlier this year for metastatic TNBC patients who have received at least two treatmentsTrodelvy's accelerated approval was based on Phase II studies, which showed an objective mitigation rate of 33.3% and a mitigation time of 7.7 monthsIn the ASCENT trial, median PFS was 5.6 months for patients treated with Trodelvy, compared with 1.7 months for chemotherapy, ByEMedics saidThe drug also reached the primary secondary endpoint of the study, including overall survival and objective mitigation ratesThe ASCENT study recruited more than 500 metastatic TNBC patients who had previously received at least two treatments for breast cancer metastasisThe safety of Trodelvy in the trial was consistent with FDA-approved labels, and neutrophil reduction and diarrhea were the most common level 3 or 4 adverse events